Celgene Earnings Preview: Can This Streak Continue?

Celgene (NASDAQ:CELG) will report earnings before markets open on Thursday, July 25th. Celgene Corporation is a global biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.

Here is your Cheat Sheet to Celgene Earnings:

Earnings Expectations: Analysts expect earnings of $1.44 per share on revenues of $1.54 billion. Currently, the company’s P/E ratio stands at 40.48.

Analyst Trends:

Analysts have a more positive outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has risen from a profit of $1.44 to a profit $1.46. For the current year, the average estimate is a profit of $5.77, which is better than the estimate ninety days ago.

Earnings Trends:

Here’s how Celgene has been performing on an annual basis:

Fiscal Year 2008 2009 2010 2011 2012
Revenue ($) in millions 2,255 2,690 3,626 4,842 5,507
Diluted EPS ($) -3.46 1.66 1.88 2.85 3.30

Next, our CHEAT SHEET investing framework asks us to drill down to the recent quarterly data:

Quarter Jun. 30, 2012 Sep. 30, 2012 Dec. 31, 2012 Mar. 31, 2013
Revenue ($) in millions 1,366.76 1,419.25 1,447.41 1,464.60
Diluted EPS ($) 0.82 0.97 0.61 0.89

Past Performance:
Celgene has beat analyst estimates 4 times in the past four quarters. Shareholders could expect a boost if the company beats estimates.

“E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our successful CHEAT SHEET investing framework. Don’t waste another minute – click here to discover our CHEAT SHEET stock picks now!

(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at] wallstcheatsheet.com)